Posts

Showing posts with the label Clear Cell Sarcoma (CCS) market outlook

Clear Cell Sarcoma (CCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Clear cell sarcoma (CCS) is a rare type comprising approximately 1% of all soft tissue sarcomas. Clear cell sarcoma is localized mainly in the lower limbs, with most cases localized in the area of the foot and ankle, where up to 40% of tumors are located. The upper limb is affected in 25% of cases. Primary CCS tumors usually develop deeply in soft tissues adjacent to tendons, fasciae, or dissections. CCS can develop at any age. However, several cases of CCS have been diagnosed over the age of 40 years. Despite slow growth and latent progression, CCS is characterized by high aggressiveness — in about 30% of patients, lymph nodes or distant metastases are present at the time of diagnosis. Unlike most sarcomas that metastasize via the circulatory system, approximately 50% of patients with CCS present with metastases in the lymph nodes. ·        The vast majority of categories of sarcomas had an incidence case ranging between 1 to 5 cases per 1,000,000....

Clear Cell Sarcoma (CCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Clear cell sarcoma (CCS) is a rare type comprising approximately 1% of all soft tissue sarcomas. Clear cell sarcoma is localized mainly in the lower limbs, with most cases localized in the area of the foot and ankle, where up to 40% of tumours are located. The upper limb is affected in 25% of cases. Primary CCS tumours usually develop deeply in soft tissues adjacent to tendons, fasciae, or dissections. CCS can develop at any age. However, several cases of CCS have been diagnosed over 40 years. Despite slow growth and latent progression, CCS is characterized by high aggressiveness — in about 30% of patients, lymph nodes or distant metastases are present at the time of diagnosis. Unlike most sarcomas that metastasize via the circulatory system, approximately 50% of patients with CCS present with metastases in the lymph nodes. ·        The vast majority of categories of sarcomas had an incidence case ranging between 1 to 5 cases per 1,000,000. The most...